false 0000946486 0000946486 2022-11-14 2022-11-14
Washington, DC 20549
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 14, 2022
Windtree Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of
incorporation or organization)
File Number)
(I.R.S. Employer
Identification No.)
2600 Kelly Road, Suite 100, Warrington, Pennsylvania
(Address of principal executive offices)
(Zip Code)
Registrants telephone number, including area code: (215) 488-9300
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Name of each exchange
on which registered
Common Stock, par value $0.001 per share
The Nasdaq Capital Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


Item 2.02
Results of Operations and Financial Condition
On November 14, 2022, Windtree Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2022. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The information contained in this Item 2.02 (including Exhibit 99.1) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section and shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 8.01
Other Events
On November 14, 2022, the Company updated information reflected in a slide presentation, which is attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference. Representatives of the Company will use the updated presentation in various meetings with investors from time to time.
Item 9.01
Financial Statements and Exhibits
(d) Exhibits
The following exhibits are being filed herewith:
Cover Page Interactive Data File (embedded within the Inline XBRL document).

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Windtree Therapeutics, Inc.
/s/ Craig E. Fraser
Craig E. Fraser
President and Chief Executive Officer
Date: November 14, 2022

Exhibit 99.1



Windtree Therapeutics Reports Third Quarter 2022
Financial Results and Provides Key Business Updates



WARRINGTON, PA November 14, 2022  Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for cardiovascular disorders, today reported financial results for the third quarter ended September 30, 2022 and provided key business updates.


“The Company had several notable deliverables this quarter and continues to focus on progressing its planned development of istaroxime. The positive results of the SEISMiC study of istaroxime in early cardiogenic shock have been well received in many scientific forums. At the same time, our team has been active in working to advance istaroxime into the next clinical trial in early cardiogenic shock. To support development and company operations, we are addressing our resources by exploring options for financing, as well as actively engaging in business development activities, both licensing and strategic,” said Craig Fraser, President and Chief Executive Officer of Windtree. “Additionally, the out-licensing of our acute pulmonary KL4 surfactant platform this quarter supports our portfolio and resource prioritization strategy as we focus on istaroxime and the significant opportunity in the major markets of cardiogenic shock and heart failure. With all that we are executing, we look forward to providing our shareholders with updates on our plans and progress.”


Key Business Updates


Announced a Global License Agreement with Lee’s Pharmaceutical (HK) Limited (Lee’s (HK)) and its affiliate Zhaoke Pharmaceutical (Hefei) Co. Ltd. (Zhaoke), for the development and commercialization of Windtree’s acute pulmonary pipeline treatments, KL4 surfactant and drug/device combination, AEROSURF®, for the treatment of preterm infants with respiratory distress syndrome and other potential applications. Under terms of the global license agreement, Lee’s (HK) and Zhaoke received a global license to develop and commercialize Surfaxin®, lyophilized lucinactant, and AEROSURF for any potential indications and applications. Lee’s (HK) and Zhaoke will be responsible for funding all development, intellectual property, manufacturing, and commercialization activities and provide developmental, regulatory, and eventual commercial sales milestones for Windtree of up to $78.9 million plus potential double-digit royalties. Windtree had previously granted a regional license to Lee’s (HK) and Zhaoke for KL4 and AEROSURF for the territory of Greater China, for which Windtree received an upfront payment, and this new agreement expands that territory globally. With the execution of this agreement, Windtree no longer has ongoing maintenance and operating costs for the KL4 surfactant platform.


Announced a Late Breaker presentation of the Company’s positive Phase 2 SEISMiC study at the Heart Failure Society of America Annual Scientific Meeting in Washington, D.C. The presentation described dose response data from the trial, where the primary endpoint was the improvement in systolic blood pressure over the first six hours of study drug infusion. Both doses improved the blood pressure profile through 24 hours.


Announced the publication of positive results of the Company’s Phase 2 istaroxime study in early cardiogenic shock in the European Journal of Heart Failure. The study entitled, “Safety and efficacy of istaroxime in patients with acute heart failure-related pre-cardiogenic shock – a multicentre, randomized, double-blind, placebo-controlled, parallel group study (SEISMiC)” showed significant improvement in blood pressure profiles that persisted through 24 hours.


Announced a Notice of Allowance from the U.S. Patent and Trademark office (USPTO) for a new istaroxime patent. A notice of allowance is issued by the USPTO to indicate that the application has passed its examination. The U.S. Patent, titled: “Istaroxime-containing Intravenous Formulation for the Treatment of Acute Heart Failure (AHF)” is a continuing patent application of the expedited U.S. Track One filing by Windtree. The claims cover longer infusion durations of istaroxime for improved outcomes in the treatment of acute heart failure. In particular, the claims are directed to an improvement in diastolic heart function following administration of istaroxime by intravenous infusion for six hours or more, which Windtree attributes to the SERCA2a mechanism of action of istaroxime and its metabolites.


Presented at two Wall Street investor conferences, including the Ladenburg Thalmann Healthcare Conference and H.C. Wainwright’s 24th Annual Global Investment Conference.


Held an Oppenheimer virtual fireside chat on istaroxime in heart failure and cardiogenic shock. The fireside chat featured perspectives from Alexandre Mebazaa, MD, PhD, of Hôpital Lariboisière, Paris, France on the immense need for pharmacologic innovation in cardiogenic shock.



Select Financial Results for the Third Quarter ended September 30, 2022


For the third quarter ended September 30, 2022, the Company reported an operating loss of $4.7 million, compared to an operating loss of $8.1 million in the third quarter of 2021. Included in operating loss for the third quarter of 2022 is non-cash expense of $0.5 million related to the impairment of goodwill


Research and development expenses were $1.5 million for the third quarter of 2022, compared to $4.7 million for the third quarter of 2021. The decrease in research and development expenses is primarily due to (i) a decrease of $1.9 million related to the KL4 surfactant platform as we continue to focus our resources on the development of our istaroxime pipeline; (ii) a decrease of $0.5 million in non-cash stock-based compensation expense; (iii) a decrease of $0.5 million for expenditures related to the development of istaroxime for AHF; and (iv) a decrease of $0.3 million following the completion of enrollment in the SEISMiC study in March 2022.


General and administrative expenses for the third quarter of 2022 were $2.7 million, compared to $3.5 million for the third quarter of 2021. The decrease in general and administrative expenses is primarily due to (i) a decrease of $0.4 million in professional fees; and (ii) a decrease of $0.4 million in non-cash stock-based compensation expense.


The Company reported a net loss of $4.1 million ($0.13 per basic share) on 31.1 million weighted-average common shares outstanding for the quarter ended September 30, 2022, compared to a net loss of $8.2 million ($0.31 per basic share) on 26.7 million weighted average common shares outstanding for the comparable period in 2021.


As of September 30, 2022, the Company reported cash and cash equivalents of $8.4 million, which is expected to be sufficient to fund operations into the second quarter of 2023.


Readers are referred to, and encouraged to read in its entirety, the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, which will be filed with the Securities and Exchange Commission on November 14, 2022, and includes detailed discussions about the Company’s business plans and operations, financial condition, and results of operations.



About Windtree Therapeutics

Windtree Therapeutics, Inc. is advancing multiple late-stage interventions for cardiovascular disorders to treat patients in moments of crisis. Using new scientific and clinical approaches, Windtree is developing a multi-asset franchise anchored around compounds with an ability to activate SERCA2a, with lead candidate, istaroxime, being developed as a first-in-class treatment for acute heart failure and for early cardiogenic shock. Windtree’s heart failure platform includes follow-on oral pre-clinical SERCA2a activator assets as well. In pulmonary care, Windtree has focused on facilitating the transfer of the KL4 surfactant platform, to its licensee, Lee’s (HK). Included in Windtree’s portfolio is rostafuroxin, a novel precision drug product targeting hypertensive patients with certain genetic profiles.


Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The Company may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are based on information available to the Company as of the date of this press release and are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the Company’s current expectations. Examples of such risks and uncertainties include: risks and uncertainties associated with the economic and social consequences of the COVID-19 pandemic, including any adverse impact on the Company’s clinical trials, clinical trial timelines or disruption in supply chain; the success and advancement of the clinical development programs for istaroxime and the Company’s other product candidates; the impacts of political unrest, including as a result of geopolitical tension, including the conflict between Russia and Ukraine, the People’s Republic of China and the Republic of China (Taiwan), and any sanctions, export controls or other restrictive actions that may be imposed by the United States and/or other countries which could have an adverse impact on the Company’s operations, including through disruption in supply chain or access to potential international clinical trial sites, and through disruption, instability and volatility in the global markets, which could have an adverse impact on the Company’s ability to access the capital markets; the Company’s ability to secure significant additional capital as and when needed; the Company’s ability to access the debt or equity markets; the Company’s ability to manage costs and execute on its operational and budget plans; the results, cost and timing of the Company’s clinical development programs, including any delays to such clinical trials relating to enrollment or site initiation; risks related to technology transfers to contract manufacturers and manufacturing development activities; delays encountered by the Company, contract manufacturers or suppliers in manufacturing drug products, drug substances, and other materials on a timely basis and in sufficient amounts; risks relating to rigorous regulatory requirements, including that: (i) the U.S. Food and Drug Administration or other regulatory authorities may not agree with the Company on matters raised during regulatory reviews, may require significant additional activities, or may not accept or may withhold or delay consideration of applications, or may not approve or may limit approval of the Company’s product candidates, and (ii) changes in the national or international political and regulatory environment may make it more difficult to gain regulatory approvals and risks related to the Company’s efforts to maintain and protect the patents and licenses related to its product candidates; risks that the Company may never realize the value of its intangible assets and have to incur future impairment charges; risks related to the size and growth potential of the markets for the Company’s product candidates, and the Company’s ability to service those markets; the Company’s ability to develop sales and marketing capabilities, whether alone or with potential future collaborators; and the rate and degree of market acceptance of the Company’s product candidates, if approved. These and other risks are described in the Company’s periodic reports, including its annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, filed with or furnished to the Securities and Exchange Commission and available at Any forward-looking statements that the Company makes in this press release speak only as of the date of this press release. The Company assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.


Contact Information:

Monique Kosse

LifeSci Advisors

212.915.3820 or




+++++ Tables to Follow +++++




Consolidated Balance Sheets


(in thousands, except share and per share data)



September 30, 2022


December 31, 2021






Current Assets:


Cash and cash equivalents

  $ 8,436     $ 22,348  

Prepaid expenses and other current assets

    1,596       1,143  

Total current assets

    10,032       23,491  

Property and equipment, net

    286       1,011  

Restricted cash

    154       154  

Operating lease right-of-use assets

    1,964       2,381  

Intangible assets

    32,070       32,070  


    3,592       15,682  

Total assets

  $ 48,098     $ 74,789  



Current Liabilities:


Accounts payable

  $ 410     $ 693  

Accrued expenses

    2,496       3,408  

Operating lease liabilities - current portion

    416       528  

Loans payable - current portion

    629       294  

Total current liabilities

    3,951       4,923  

Operating lease liabilities - non-current portion

    1,732       2,071  

Restructured debt liability - contingent milestone payments

    15,000       15,000  

Other liabilities

    3,800       3,800  

Deferred tax liabilities

    6,195       7,114  

Total liabilities

    30,678       32,908  

Stockholders’ Equity:


Preferred stock, $0.001 par value; 5,000,000 shares authorized; 0 shares issued and outstanding

    -       -  

Common stock, $0.001 par value; 120,000,000 shares authorized at September 30, 2022 and December 31, 2021; 32,646,735 and 28,268,950 shares issued at September 30, 2022 and December 31, 2021, respectively; 32,646,711 and 28,268,926 shares outstanding at September 30, 2022 and December 31, 2021, respectively

    33       28  

Additional paid-in capital

    835,281       830,231  

Accumulated deficit

    (814,840 )     (785,324 )

Treasury stock (at cost); 24 shares

    (3,054 )     (3,054 )

Total stockholders’ equity

    17,420       41,881  

Total liabilities & stockholders’ equity

  $ 48,098     $ 74,789  




Consolidated Statements of Operations


(in thousands, except per share data)



Three Months Ended


Nine Months Ended


September 30,


September 30,












Research and development

  $ 1,543     $ 4,680     $ 9,883     $ 13,311  

General and administrative

    2,653       3,467       8,548       11,507  

Loss on impairment of goodwill

    454       -       12,090       -  

Loss on impairment of intangible assets

    -       -       -       37,770  

Total operating expenses

    4,650       8,147       30,521       62,588  

Operating loss

    (4,650 )     (8,147 )     (30,521 )     (62,588 )

Other income (expense):


Interest income

    39       1       57       90  

Interest expense

    (14 )     (14 )     (40 )     (101 )

Other income (expense), net

    569       (53 )     988       (296 )

Total other income (expense), net

    594       (66 )     1,005       (307 )

Loss before income taxes

    (4,056 )     (8,213 )     (29,516 )     (62,895 )

Deferred income tax benefit

    -       -       -       8,332  

Net loss

  $ (4,056 )   $ (8,213 )   $ (29,516 )   $ (54,563 )

Net loss per common share


Basic and diluted

  $ (0.13 )   $ (0.31 )   $ (1.00 )   $ (2.31 )

Weighted average number of common shares outstanding


Basic and diluted

    31,135       26,704       29,554       23,616  


Image Exhibit

Exhibit 99.2